BioSpace News Archive

Rhythm Pharmaceuticals, Inc. announced plans to add a cohort of patients with hypothalamic obesity in Japan to its ongoing global Phase 3 clinical trial of setmelanotide, with dosing expected to begin in the third quarter of 2024.

Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the full year 2023.

Monopar Therapeutics Inc. today announced promising preclinical imaging and therapeutic efficacy data for its MNPR-101 radiopharmaceutical program.

Karyopharm Therapeutics Inc. today announced it will report fourth quarter and full year 2023 financial results on Thursday, February 29, 2024.

908 Devices Inc. today announced it will participate in the following investor conferences.

Amylyx Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2023.

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (“Bausch Health” the “Company,” “we” or “our”) today announced its fourth-quarter and full-year 2023 financial results.

Ocular Therapeutix, Inc. today announced that it has granted inducement equity awards to its newly appointed Executive Chairman, Pravin U. Dugel, MD and to its newly appointed Chief Strategy Officer, Sanjay Nayak, MBBS, PhD.

Ocular Therapeutix, Inc. today announced Board of Directors and leadership updates with the addition of Pravin U. Dugel, MD as Executive Chairman and the additions of Jeffrey S. Heier, MD, Peter K. Kaiser, MD, and Sanjay Nayak, MBBS, PhD to the Ocular management team as Chief Scientific Officer, Medical Director, and Chief Strategy Officer, respectively.

InflaRx N.V., a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced the appointment of Jan Medina, CFA, as Vice President and Head of Investor Relations of InflaRx.